When administered orally, the recommended dosage for refractory CTCL is 300 mg/m2/day, with the maximum dosage being 400 mg/m2/day.[1] Bexarotene is administered once daily. The oral administration allows for treatment to be undertaken at home. This has the potential to decrease both the inconvenience to the patient and the cost to the healthcare system compared with those for alternatives requiring delivery in a clinical setting (e.g. UVA and UVB irradiation, photopheresis, electron beam radiation and interferon-).[2]
Also convenient is the availability of a topical formulation. Most patients tolerate the 1% topical formulation.[1] The frequency of application is modified on the basis of response and tolerability, and is typically between 1 to 4 times daily.
Bexarotene (oral and topical) is contraindicated in pregnant women and women intending to become pregnant.
Linkback:
https://tubagbohol.mikeligalig.com/index.php?topic=20414.0
Topic: Dosage and Administration (Read 919 times)